AbbVie Inc (ABBV) reported better-than-expected financial results for the third quarter of fiscal 2025. The company posted earnings per share (EPS) of $1.86, exceeding Wall Street's consensus estimate of $1.81 by $0.05. Revenue reached $15.8 billion, slightly below the anticipated $15.9 billion.
The earnings report highlights AbbVie's operational performance and financial health. The firm, headquartered in North Chicago, Illinois, specializes in biopharmaceuticals and employs approximately 55,000 people. Its diverse product portfolio includes treatments in immunology, oncology, aesthetics, and neuroscience.
AbbVie will host an earnings conference call at BMO to discuss these results further and provide insights into business performance.
Investors are encouraged to review the full earnings release and listen to management's commentary for a comprehensive understanding of the quarter's performance and future outlook. Upcoming earnings are scheduled for July 28, 2026, with an EPS estimate of $3.75 and revenue expectation of $17.0 billion.